LARIMAR THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
LARIMAR THERAPEUTICS, INC. (LRMR) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of -0.10% for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-05.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2020-03-05
- LARIMAR THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2019 was -0.10%.
- LARIMAR THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2018 was -0.90%.
- LARIMAR THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2017 was -1.40%.
- LARIMAR THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2016 was 0.00%, a 100.00% decline from fiscal 2015.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month as first filed |
|---|---|---|
| 2019-12-31 | -0.10% 10-K · filed 2020-03-05 | |
| 2018-12-31 | -0.90% 10-K · filed 2020-03-05 | |
| 2017-12-31 | -1.40% 10-K · filed 2020-03-05 | 1.40% 10-K · filed 2018-03-09 |
| 2016-12-31 | 0.00% 10-K · filed 2019-03-14 | |
| 2015-12-31 | 1.00% 10-K · filed 2018-03-09 | |
| 2014-12-31 | 0.60% 10-K · filed 2017-03-10 | |
| 2013-12-31 | 4.10% 10-K · filed 2016-03-15 | |
| 2012-12-31 | 1.80% 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |